05-530-I Sigma-AldrichAnti-Rad51 Antibody, clone 3C10
This Anti-Rad51 Antibody, clone 3C10 is validated for use in Western Blotting, Immunoprecipitation for the detection of Rad51 .
More>> This Anti-Rad51 Antibody, clone 3C10 is validated for use in Western Blotting, Immunoprecipitation for the detection of Rad51 . Less<<Recommended Products
Overview
| Replacement Information |
|---|
Key Spec Table
| Species Reactivity | Key Applications | Host | Format | Antibody Type |
|---|---|---|---|---|
| H | WB, IP | M | Purified | Monoclonal Antibody |
| References |
|---|
| Product Information | |
|---|---|
| Format | Purified |
| Presentation | Purified mouse monoclonal IgG1κ antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide. |
| Quality Level | MQ100 |
| Physicochemical Information |
|---|
| Dimensions |
|---|
| Materials Information |
|---|
| Toxicological Information |
|---|
| Safety Information according to GHS |
|---|
| Safety Information |
|---|
| Storage and Shipping Information | |
|---|---|
| Storage Conditions | Stable for 1 year at 2-8°C from date of receipt. |
| Packaging Information | |
|---|---|
| Material Size | 200 μg |
| Transport Information |
|---|
| Supplemental Information |
|---|
| Specifications |
|---|
| Global Trade Item Number | |
|---|---|
| Catalogue Number | GTIN |
| 05-530-I | 04055977173369 |
Documentation
Anti-Rad51 Antibody, clone 3C10 SDS
| Title |
|---|
Anti-Rad51 Antibody, clone 3C10 Certificates of Analysis
| Title | Lot Number |
|---|---|
| Anti-Rad51, clone 3C10 (mouse monoclonal) Monoclonal Antibody | Q2922327 |
| Anti-Rad51, clone 3C10 - 3436195 | 3436195 |
| Anti-Rad51, clone 3C10 - 3832627 | 3832627 |
| Anti-Rad51, clone 3C10 - 3931783 | 3931783 |
| Anti-Rad51, clone 3C10 - 4137149 | 4137149 |
| Anti-Rad51, clone 3C10 - 4149123 | 4149123 |
| Anti-Rad51, clone 3C10 -Q2574784 | Q2574784 |
Technical Info
| Title |
|---|
| Characterization of Estrogen Receptor α Phosphorylation Sites in Breast Cancer Tissue Using the SNAP i.d® 2.0 System |
| White Paper: Further considerations of antibody validation and usage. |



